Stock ALKEM ALKEM LABORATORIES LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Alkem Laboratories Limited Bombay S.E.

Equities

ALKEM

INE540L01014

Pharmaceuticals

Market Closed - Bombay S.E.
Other stock markets
 06:00:58 2024-07-05 am EDT 		5-day change 1st Jan Change
5,063 INR +1.73% Intraday chart for Alkem Laboratories Limited +1.44% -2.49%
Jun. 25 Alkem Laboratories Gets 'Voluntary Action Indicated' for Baddi, India Facility; Shares Jump 4% MT
Jun. 14 Alkem Laboratories Limited Announces Resignation of Dheeraj Sharma as an Independent Director CI

Valuation

Fiscal Period: March 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 209,340 278,090 331,171 432,909 406,055 605,423 - -
Enterprise Value (EV) 1 211,750 283,796 328,603 433,805 393,853 587,236 588,625 572,539
P/E ratio 27.5 x 24.7 x 20.9 x 26.3 x 41.3 x 32.9 x 28.3 x 24.4 x
Yield 0.91% 1.07% 1.01% 0.94% 0.74% 0.81% 0.92% 1.12%
Capitalization / Revenue 2.85 x 3.33 x 3.74 x 4.07 x 3.5 x 4.66 x 4.33 x 3.92 x
EV / Revenue 2.88 x 3.4 x 3.71 x 4.08 x 3.4 x 4.64 x 4.21 x 3.7 x
EV / EBITDA 19 x 19.3 x 16.9 x 21.1 x 24.5 x 26.2 x 22.8 x 19.3 x
EV / FCF 85.3 x 120 x 30.4 x 55.4 x 27.1 x 33.3 x 50.2 x 34.8 x
FCF Yield 1.17% 0.84% 3.29% 1.81% 3.69% 3% 1.99% 2.88%
Price to Book 3.85 x 4.51 x 4.49 x 5.01 x 4.49 x 5.73 x 5.17 x 4.5 x
Nbr of stocks (in thousands) 119,565 119,565 119,565 119,565 119,565 119,565 - -
Reference price 2 1,751 2,326 2,770 3,621 3,396 5,064 5,064 5,064
Announcement Date 5/30/19 6/5/20 5/25/21 5/13/22 5/19/23 5/29/24 - -
1INR in Million2INR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: March 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 73,572 83,444 88,650 106,342 115,993 126,676 139,911 154,532
EBITDA 1 11,148 14,734 19,424 20,529 16,094 22,455 25,823 29,622
EBIT 1 9,216 12,206 16,678 17,490 12,990 19,462 22,296 25,908
Operating Margin 12.53% 14.63% 18.81% 16.45% 11.2% 15.36% 15.94% 16.77%
Earnings before Tax (EBT) 1 9,547 12,598 18,421 18,443 13,048 20,231 24,852 28,988
Net income 1 7,605 11,271 15,850 16,456 9,842 17,958 21,453 24,867
Net margin 10.34% 13.51% 17.88% 15.47% 8.48% 14.18% 15.33% 16.09%
EPS 2 63.61 94.26 132.6 137.6 82.31 150.2 179.0 207.3
Free Cash Flow 1 2,482 2,374 10,804 7,830 14,528 17,613 11,729 16,473
FCF margin 3.37% 2.85% 12.19% 7.36% 12.52% 13.9% 8.38% 10.66%
FCF Conversion (EBITDA) 22.27% 16.12% 55.62% 38.14% 90.27% 78.44% 45.42% 55.61%
FCF Conversion (Net income) 32.64% 21.07% 68.17% 47.58% 147.62% 98.08% 54.68% 66.24%
Dividend per Share 2 16.00 25.00 28.00 34.00 25.00 40.00 46.57 56.93
Announcement Date 5/30/19 6/5/20 5/25/21 5/13/22 5/19/23 5/29/24 - -
1INR in Million2INR
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: March 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 23,180 21,922 27,314 28,000 26,190 24,839 25,764 30,794 30,409 29,026 29,677 33,575 32,679 31,959 32,585
EBITDA 1 5,291 2,911 5,929 6,244 4,985 3,372 2,032 4,539 5,990 3,532 3,892 5,371 6,025 4,634 5,372
EBIT 1 4,601 2,226 5,223 5,516 4,210 2,541 1,270 3,765 5,206 2,749 3,168 4,722 5,200 4,496 6,033
Operating Margin 19.85% 10.15% 19.12% 19.7% 16.07% 10.23% 4.93% 12.23% 17.12% 9.47% 10.67% 14.06% 15.91% 14.07% 18.51%
Earnings before Tax (EBT) 1 5,434 2,582 5,561 5,815 4,639 2,427 1,519 4,023 5,389 2,117 3,528 4,800 5,500 4,596 6,457
Net income 1 4,510 2,400 4,681 5,443 5,257 1,076 1,276 3,308 4,547 709.8 2,867 4,005 4,711 3,682 5,707
Net margin 19.45% 10.95% 17.14% 19.44% 20.07% 4.33% 4.95% 10.74% 14.95% 2.45% 9.66% 11.93% 14.42% 11.52% 17.51%
EPS 37.72 20.07 39.15 45.52 43.96 9.000 10.68 27.67 38.03 - - 28.50 - 34.00 47.60
Dividend per Share - - - - - - - - - - - - - - -
Announcement Date 2/5/21 5/25/21 8/6/21 11/12/21 2/4/22 5/13/22 8/5/22 11/11/22 2/10/23 5/19/23 8/10/23 - - - -
1INR in Million
Estimates

Balance Sheet Analysis

Fiscal Period: March 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 2,410 5,705 - 896 - - - -
Net Cash position 1 - - 2,569 - 12,202 3,654 16,798 32,884
Leverage (Debt/EBITDA) 0.2162 x 0.3872 x - 0.0437 x - - - -
Free Cash Flow 1 2,483 2,374 10,805 7,830 14,528 17,613 11,729 16,473
ROE (net income / shareholders' equity) 14.8% 19.4% 23.4% 20.7% 15.9% 18.6% 18.8% 19.2%
ROA (Net income/ Total Assets) 9.58% 12.4% 14.8% 13% 10.1% 12.2% 13.2% 13.6%
Assets 1 79,369 90,761 107,324 126,892 97,269 146,658 162,914 182,562
Book Value Per Share 2 455.0 515.0 617.0 723.0 757.0 863.0 980.0 1,126
Cash Flow per Share 2 65.00 48.90 106.0 92.90 141.0 163.0 135.0 177.0
Capex 1 5,269 3,476 1,845 3,280 2,297 2,593 5,696 3,903
Capex / Sales 7.16% 4.17% 2.08% 3.08% 1.98% 2.05% 4.07% 2.53%
Announcement Date 5/30/19 6/5/20 5/25/21 5/13/22 5/19/23 5/29/24 - -
1INR in Million2INR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Alkem Laboratories Limited

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
21
Last Close Price
5,064 INR
Average target price
5,195 INR
Spread / Average Target
+2.59%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+56.89% 823B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+39.52% 627B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.55% 353B
MERCK & CO., INC. Stock Merck & Co., Inc.
+15.99% 320B
ABBVIE INC. Stock AbbVie Inc.
+7.92% 295B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.74% 239B
NOVARTIS AG Stock Novartis AG
+13.83% 220B
ROCHE HOLDING AG Stock Roche Holding AG
-0.49% 219B
AMGEN INC. Stock Amgen Inc.
+7.94% 167B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. ALKEM Stock
  4. ALKEM Stock
  5. Financials Alkem Laboratories Limited